Stocks Fall as Sliding Oil Prices Hit Energy Shares

Stocks around the world fell Tuesday as sliding oil prices added to concerns about the health of the global economy.

With ‘Viability’ Rule, O’Malley Backers Could Tip the Vote

A Democratic caucus “viability” rule makes backers of low-polling former Maryland Gov. Martin O’Malley strategically important to the Sanders and Clinton campaigns.

U.S. Stocks Slip as Oil Prices Slide, China Data Disappoints

U.S. stocks fell Monday along with oil prices, pulling back after major indexes notched their biggest-one day rally since the fall. Fresh signs of weakness in China’s manufacturing sector added to concerns.

The Life of the Party

Republicans need to draw the right lessons from the Trump insurgency. And Democrats should take note.

The Brazilian Doctors Who Sounded Alarm on Zika and Microcephaly

The van der Linden family of physicians identified a likely link between the virus and a spike in birth defects involving incomplete brain development.

Stocks Rally as BOJ Cuts Rates Into Negative Territory

A surprise interest rate cut from Japan’s central bank boosted stocks around the world, capping a turbulent month for financial markets.

What to Watch for in the Fourth-Quarter GDP Report

Economists surveyed by The Wall Street Journal forecast a paltry 0.8% seasonally adjusted annual growth rate for gross domestic product, the broadest measure of output.

Dollar’s Rise Poses Risk for Fed Plans

As Federal Reserve officials prepare to release interest-rate guidance Wednesday, investors are bracing for the dollar to renew its rise against America’s major trading partners and intensify unrest throughout the world’s financial markets.

Super Bowl TV Ads Reign, Even in a Digital World

While Super Bowl ads still land the biggest bottom-line punch for companies, pairing those spots with digital ads in the weeks surrounding the big game is the best way to get the most bang for the buck, ad executives say.

Problems Found at Theranos Lab

U.S. health inspectors have found serious deficiencies at Theranos’s laboratory in Northern California, and failing to fix them could put the lab at risk of suspension from the Medicare program.